CAS: 6493-05-6; 3,7-Dimethyl-1-(5-Oxohexyl)-1H-Purine-2,6(3H,7H)-Dione

上下游产品

CAS号83-67-0 可可碱 | CAS号10226-29-6 6-溴-2-己酮 | CAS号6493-06-7 (±)-Lisofylline

1-(4-Chlorobutyl)-3,7-Dimethyl-3,7-Dihydro-1H-Purine-2,6-Dione置于锰,(2-(Dimethylamino)-N-(Quinolin-8-yl)Acetamido)Nickel(II) Chloride,Sodium Iodide体系中,用 N,N-二甲基甲酰胺,丙酮 作为反应溶剂,化学反应 16.0H,反应生成 己酮可可碱
参考文献:直接访问由nickel(i)激活介导的同位素标记的脂肪族酮.
标题:直接访问由nickel(i)激活介导的同位素标记的脂肪族酮.
摘要:通过伯或仲烷基碘的nii促进与nn2钳制的niii-酰基络合物的nii促进的偶联,已经制备了具有非常好的官能团耐受性的各种官能化脂肪族酮.后者可以容易地从具有化学计量比的co的相应niii-烷基络合物中获得.这种ni介导的羰基化偶联适合于后期碳同位素标记,如同位素标记药物的制备所示.初步研究表明,以碳为中心的自由基是中间的.
DOI:10.1002/anie.201916391

专利信息

专利号:US-2014046060-A1
优先权日:2010-09-01
标 题 :Method of utilizing recycled deuterium oxide in the synthesis of deuterated compounds
发明人：JONES ANDREW D; PAUL BERNHARD J
权利人:JONES ANDREW D; PAUL BERNHARD J; CONCERT PHARMACEUTICALS INC
摘要:The present invention provides a method for utilizing recycled deuterium oxide synthesis of deuterated compounds.

专利号:US-5043328-A
优先权日:1986-05-09
标 题 :Formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems
发明人：WEITHMANN KLAUS U
权利人:HOECHST AG
摘要:The present invention relates to formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems and to the use of such formulations for the preparation of medicaments which are suitable for curing prostaglandin deficiencies in humans or animal, for example healing or preventing diseases of the gastro-intestinal tract.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-5763625-A
优先权日:1995-04-25
标 题:Synthesis and use of β-lapachone analogs
发明人：BOOTHMAN DAVID A; FRYDMAN BENJAMIN J; WITIAK DONALD T
权利人:WISCONSIN ALUMNI RES FOUND
摘要:3-Substituted-β-lapachone analogs and their use either alone or to augment chemotherapy or radiotherapy to induce programmed neoplastic cell death without exhibiting toxicity to surrounding normal cells are disclosed. In particular, 3-allyl-β-lapachones, 3-alkyl-β-lapachones and 3-halo-β-lapachones were found to be Topoisomerase (Topo I) inhibitors. When these analogs are used alone there is a reversible single-strand break in the DNA of neoplastic cells causing apoptosis and cell death in some cells. However, when these analogs are combined with chemotherapy or X-irradiation, an irreversible Topo I-mediated break is achieved. A new and more efficient chemical synthesis of the compounds is also disclosed.

专利号:US-2003157061-A1
优先权日:2001-12-05
标 题 :Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor
发明人：BENNETT DENNIS A
权利人:PHARMACIA CORP
摘要:A method for the prevention, treatment, or inhibition of pain, inflammation, or inflammation-related disorder and for the prevention, treatment, or inhibition of a cardiovascular disease or disorder in a subject that is in need of such prevention, treatment or inhibition, involves the administration to the subject of a cyclooxygenase-2 selective inhibitor or prodrug thereof and a TNFα antagonist. A method can also involve the treatment, prevention, or inhibition of cancer in a subject in need of such treatment, prevention, or inhibition, by administering to the subject a cyclooxygenase-2 selective inhibitor or prodrug thereof and a TNFα antagonist which is selected from the group consisting of a compound that affects the synthesis of TNFα, a compound that inhibits the binding of TNFα with a receptor specific for TNFα, and a compound that interferes with intracellular signaling triggered by TNFα binding with a receptor. Compositions, pharmaceutical compositions and kits that can be used with the methods are also described.

专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人：PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.